Page 8 - Reflections_dyslipidaemia_newsletter4_2023

REFLECTIONS
Dyslipidaemia
Dyslipidaemia Global Newsletter #4 2023

Dyslipidaemia

With regards to key secondary efficacy endpoints, the risk of events with respect to a three-component MACE (death from CV
causes, non-fatal MI, or non-fatal stroke), fatal or non-fatal MI, and coronary revascularization, were all significantly lower in the
bempedoic acid group compared to the placebo group. The secondary efficacy endpoints of death from CV causes and death from
any cause were not significantly different between the two groups.

The incidence of adverse events were similar in the
two groups overall; however, the bempedoic acid
group had higher incidences of elevated hepatic
enzymes, renal impairment, hyperuricemia, gout,
and cholelithiasis.

The effects of bempedoic acid are consistent with
the event reduction predicted in the meta-analysis
by the Cholesterol Treatment Trialists Collaboration.
The time-averaged reduction in LDL-C of 22.0 mg/
dL over the duration of the trial would be expected to
lead to the approximate relative reduction in the risk
of CV events that was observed.

The authors commented that the trial included only patients who were unable or unwilling to take statins, and therefore the mean
LDL-C level was high at baseline. The findings therefore cannot be generalized to populations with lower LDL-C levels or in patients
taking conventional therapeutic doses of statins.

WATCH A SHORT VIDEO SUMMARY OF CLICK HERE
THE ARTICLE HERE (2:22 MIN). FOR THE LINK TO FULL ARTICLE

TABLE OF CONTENTS